Senate investigations panel to probe Mylan's EpiPen pricing
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get daily under-the-radar research with StreetInsider.com's Stealth Growth Insider Get your 2-Wk Free Trial here.
WASHINGTON (Reuters) - The U.S. Senate's permanent subcommittee on investigations will probe Mylan Pharmaceuticals' pricing of the allergy auto-injector EpiPen, according to a press release issued on Wednesday.
The release described the probe as a "preliminary inquiry."
Mylan has been criticized - including by Democratic presidential candidate Hillary Clinton - for sharply raising the price of EpiPens, which are carried by people with life-threatening allergies. Mylan raised the price from about $100 in 2008 to about $600 currently. It has offered some discounts but this has done little to allay concerns.
"Our review of this matter will be robust, thorough, and bipartisan. Parents and school districts in Ohio, Missouri and across the country need affordable access to this life-saving drug, and we share their concern over Mylan’s sustained price increases," Senators Rob Portman, the Republican chair of the subcommittee, and Claire McCaskill, the top Democrat, said in a statement.
Mylan did not immediately respond to a request for comment.
(Reporting by Diane Bartz; Editing by Chris Reese and Andrew Hay)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Netflix (NFLX) Long-Term Thesis Still Playing Out, Remains Top Pick - RBC Capital
- Trump says he respects CIA in his first visit to headquarters
- Japan enters uncharted waters as emperor's abdication pondered
Create E-mail Alert Related CategoriesReuters
Related EntitiesRaising Prices
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!